All In Biotech

NDA 208193 · Rosemont

Ozobax Ds

Baclofen · Oral · gamma-Aminobutyric Acid-ergic Agonist

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Sep 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

123

30 Phase 3, 6 recruiting

FAERS reports

85,283

56,416 serious, 6,383 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

Baclofen oral solution is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Baclofen oral solution may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Limitations of Use Baclofen oral solution is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. Baclofen oral solution is a gamma-aminobutyric acid (GABA-ergic) agonist indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. ( 1 ) Baclofen oral solution may also be of some value in patients with spinal cord injuries and other spinal cord diseases. ( 1 ) Limitations of Use Baclofen oral solution is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. ( 1 )

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • OZOBAX DS · BACLOFEN 10MG/5ML · SOLUTION, ORAL · Prescription · TE AA
  • OZOBAX · BACLOFEN 5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.

All 123 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue6,301
  • drug ineffective5,648
  • pain5,558
  • fall5,451
  • nausea4,694
  • headache4,446
  • gait disturbance4,135
  • off label use3,878
  • dizziness3,633
  • urinary tract infection3,526
  • asthenia3,445
  • multiple sclerosis relapse3,419

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004646
2005757
2006675
2007795
2008886
20091,033
20101,500
20111,738
20122,502
20133,001
20144,251
20155,157
20167,596
20177,023
20187,705
20196,672
20205,778
20215,493
20225,107
20235,680
20244,233
20254,069
20262,983

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ozobax Ds (Baclofen)

2024 spending

$32K

Beneficiaries

11

24 claims

Per beneficiary

$2,902

$3.30 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$31,920

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 558 on PubMed

Sponsor: Rosemont · Also marketed as Ozobax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.